

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D. C. 20549

**FORM 8-K**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**October 20, 2021**

Date of Report (Date of earliest event reported)

**ABBOTT LABORATORIES**

(Exact name of registrant as specified in charter)

**Illinois**  
(State or other Jurisdiction  
of Incorporation)

**1-2189**  
(Commission File Number)

**36-0698440**  
(IRS Employer  
Identification No.)

**100 Abbott Park Road**  
**Abbott Park, Illinois 60064-6400**  
(Address of principal executive offices)(Zip Code)

Registrant's telephone number, including area code: **(224) 667-6100**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section 12(b) of the Act:

<b>Title of Each Class</b>	<b>Trading Symbol(s)</b>	<b>Name of Each Exchange on Which Registered</b>
Common Shares, Without Par Value	ABT	New York Stock Exchange Chicago Stock Exchange, Inc.

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

## Item 2.02 Results of Operations and Financial Condition

On October 20, 2021, Abbott Laboratories announced its results of operations for the third quarter 2021.

Furnished as Exhibit 99.1, and incorporated herein by reference, is the news release issued by Abbott announcing those results. In that news release, Abbott uses various non-GAAP financial measures including, among others, net earnings from continuing operations excluding specified items. These non-GAAP financial measures adjust for factors that are unusual or unpredictable, such as expenses primarily associated with acquisitions, restructuring actions, cost reduction initiatives, certain litigation, the acquisition of an R&D asset, the impairment of certain assets, the gain on the disposition of an equity method investment, tax benefits associated with specified items, and excess tax benefits associated with share-based compensation. These non-GAAP financial measures also exclude intangible amortization expense to provide greater visibility on the results of operations excluding these costs, similar to how Abbott's management internally assesses performance. Abbott's management believes the presentation of these non-GAAP financial measures provides useful information to investors regarding Abbott's results of operations as these non-GAAP financial measures allow investors to better evaluate ongoing business performance. Abbott's management also uses these non-GAAP financial measures internally to monitor performance of the businesses. Abbott, however, cautions investors to consider these non-GAAP financial measures in addition to, and not as a substitute for, financial measures prepared in accordance with GAAP.

### Item 9.01 Financial Statements and Exhibits

<u>Exhibit No.</u>	<u>Exhibit</u>
<a href="#">99.1</a>	<a href="#">Press Release dated October 20, 2021 (furnished pursuant to Item 2.02).</a>
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ABBOTT LABORATORIES**

Date: October 20, 2021

By: /s/ Robert E. Funck, Jr.

Robert E. Funck, Jr.  
Executive Vice President, Finance  
and Chief Financial Officer

---



## Abbott Reports Third-Quarter 2021 Results; Achieves Strong Double-Digit Earnings Growth and Raises Guidance

- **Third-quarter sales growth of 23.4 percent; organic sales growth of 22.4 percent**
- **GAAP diluted EPS from continuing operations growth of 69.6 percent; adjusted diluted EPS growth of 42.9 percent**
- **Global COVID-19 testing-related sales were \$1.9 billion in the third quarter**
- **Excluding COVID-19 testing-related sales, third-quarter sales grew 11.7 percent on both a reported and organic basis compared to sales in 2019**
- **Continues to strengthen portfolio with several new product approvals**

ABBOTT PARK, Ill., Oct. 20, 2021 — Abbott today announced financial results for the third quarter ended Sept. 30, 2021.

- Third-quarter sales of \$10.9 billion increased 23.4 percent on a reported basis and 22.4 percent on an organic basis, which excludes the impact of foreign exchange.
- Third-quarter GAAP diluted EPS was \$1.17 and adjusted diluted EPS, which excludes specified items, was \$1.40, reflecting 42.9 percent growth versus the prior year.<sup>1</sup>
- Abbott projects full-year 2021 diluted EPS from continuing operations on a GAAP basis of \$3.55 to \$3.65 and full-year adjusted diluted EPS from continuing operations of \$5.00 to \$5.10, reflecting growth of 38.4 percent at the mid-point versus prior year.<sup>2</sup>
- In August, Abbott announced U.S. FDA approval of its Amplatzer® Amulet® device, which offers immediate closure of the left atrial appendage – an area in the heart where blood clots can form.
- In August, Abbott announced results of the company's GUIDE-HF clinical trial, which showed Abbott's CardioMEMS® remote monitoring system can improve care for more patients living with heart failure. Abbott filed a Premarket Approval (PMA) supplement with the FDA for consideration of an expanded indication for CardioMEMS.
- In September, Abbott announced U.S. FDA approval of its Portico® with FlexNav® transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high or extreme risk for open-heart surgery.
- During the third quarter, Abbott acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots.

"We achieved another quarter of strong growth overall and across all four of our major business areas," said Robert B. Ford, president and chief executive officer, Abbott. "We're particularly pleased with the continued advancements of our new product pipeline, including several recent launches in large, high-growth markets."

—more—

### THIRD-QUARTER BUSINESS OVERVIEW

Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business. Organic sales growth excludes the impact of foreign exchange.

Following are sales by business segment and commentary for the third quarter 2021:

#### Total Company

(\$ in millions)

	Sales 3Q21			% Change vs. 3Q20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total *</b>	4,368	6,560	10,928	31.2	18.7	23.4	31.2	17.0	22.4
Nutrition	919	1,189	2,108	12.3	7.6	9.6	12.3	6.5	8.9
Diagnostics	1,947	1,965	3,912	71.8	30.5	48.2	71.8	28.0	46.8
Established Pharmaceuticals	--	1,265	1,265	n/a	15.1	15.1	n/a	15.3	15.3
Medical Devices	1,496	2,136	3,632	9.7	18.2	14.6	9.7	15.7	13.1

\* Total Q3 2021 Abbott sales from continuing operations include Other Sales of approximately \$11 million.

	Sales 9M21			% Change vs. 9M20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total *</b>	11,787	19,820	31,607	33.6	31.4	32.2	33.6	27.3	29.6
Nutrition	2,628	3,624	6,252	7.8	10.7	9.5	7.8	8.7	8.3
Diagnostics	4,743	6,430	11,173	69.8	75.3	73.0	69.8	68.7	69.2
Established Pharmaceuticals	--	3,515	3,515	n/a	11.4	11.4	n/a	12.0	12.0
Medical Devices	4,385	6,233	10,618	23.1	25.5	24.5	23.1	19.0	20.7

\* Total 9M 2021 Abbott sales from continuing operations include Other Sales of approximately \$49 million.

n/a = Not Applicable.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.

Third-quarter 2021 worldwide sales of \$10.9 billion increased 23.4 percent on a reported basis and 22.4 percent on an organic basis.

Compared to pre-pandemic sales in 2019, worldwide sales, excluding COVID-19 testing-related sales<sup>3</sup>, increased 11.7 percent on both a reported and organic basis in the third quarter.

**Nutrition**

(\$ in millions)

	Sales 3Q21			% Change vs. 3Q20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total</b>	919	1,189	2,108	12.3	7.6	9.6	12.3	6.5	8.9
Pediatric	586	514	1,100	20.2	(0.8)	9.4	20.2	(2.2)	8.6
Adult	333	675	1,008	0.6	15.0	9.8	0.6	14.1	9.3

	Sales 9M21			% Change vs. 9M20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total</b>	2,628	3,624	6,252	7.8	10.7	9.5	7.8	8.7	8.3
Pediatric	1,622	1,637	3,259	8.9	0.5	4.5	8.9	(1.7)	3.4
Adult	1,006	1,987	2,993	6.0	20.9	15.5	6.0	18.9	14.2

Worldwide Nutrition sales increased 9.6 percent on a reported basis and 8.9 percent on an organic basis in the third quarter. Strong performance of Ensure<sup>®</sup>, Abbott's market-leading complete and balanced nutrition brand, and Glucerna<sup>®</sup>, Abbott's market-leading diabetes nutrition brand, led to global Adult Nutrition sales growth of 9.8 percent on a reported basis and 9.3 percent on an organic basis.

Worldwide Pediatric Nutrition sales increased 9.4 percent on a reported basis and 8.6 percent on an organic basis. Strong performance of Abbott's market-leading oral hydration brand, Pedialyte<sup>®</sup>, and continued share growth in infant nutrition led to U.S. Pediatric Nutrition growth of 20.2 percent.

**Diagnostics**

(\$ in millions)

	Sales 3Q21			% Change vs. 3Q20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total</b>	1,947	1,965	3,912	71.8	30.5	48.2	71.8	28.0	46.8
Core Laboratory	291	1,001	1,292	2.4	12.2	9.9	2.4	9.9	8.1
Molecular	162	183	345	(26.2)	(23.1)	(24.6)	(26.2)	(25.0)	(25.6)
Point of Care	100	35	135	3.9	1.5	3.3	3.9	(0.1)	2.8
Rapid Diagnostics	1,394	746	2,140	161.4	118.5	144.7	161.4	115.0	143.3

	Sales 9M21			% Change vs. 9M20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total</b>	4,743	6,430	11,173	69.8	75.3	73.0	69.8	68.7	69.2
Core Laboratory	845	2,935	3,780	0.6	26.9	19.9	0.6	22.1	16.4
Molecular	431	651	1,082	0.5	23.5	13.2	0.5	17.6	9.9
Point of Care	289	112	401	4.0	2.5	3.6	4.0	(1.0)	2.6
Rapid Diagnostics	3,178	2,732	5,910	154.9	280.1	200.7	154.9	266.6	195.8

Worldwide Diagnostics sales increased 48.2 percent on a reported basis in the third quarter and increased 46.8 percent on an organic basis. Global COVID-19 testing-related sales were \$1.9 billion in the third quarter, led by combined sales of \$1.6 billion from Abbott's BinaxNOW<sup>®</sup>, Panbio<sup>®</sup> and ID NOW<sup>®</sup> rapid testing platforms. Excluding COVID-19 testing-related sales, worldwide diagnostics sales increased 14.1 percent on a reported basis in the third quarter and 12.5 percent on an organic basis.<sup>4</sup>

Compared to the pre-pandemic 2019 baseline, sales in Core Laboratory and Molecular Diagnostics, excluding COVID-19 testing-related sales, grew 5.8 percent and 14.9 percent, respectively, on a reported basis in the third quarter and grew 4.9 percent and 13.6 percent, respectively, on an organic basis.<sup>5</sup>

**Established Pharmaceuticals**

(\$ in millions)

	Sales 3Q21			% Change vs. 3Q20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total</b>	--	1,265	1,265	n/a	15.1	15.1	n/a	15.3	15.3
Key Emerging Markets	--	936	936	n/a	17.1	17.1	n/a	17.9	17.9
Other	--	329	329	n/a	9.7	9.7	n/a	8.5	8.5

	Sales 9M21			% Change vs. 9M20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total</b>	--	3,515	3,515	n/a	11.4	11.4	n/a	12.0	12.0
Key Emerging Markets	--	2,672	2,672	n/a	12.4	12.4	n/a	14.2	14.2
Other	--	843	843	n/a	8.1	8.1	n/a	5.4	5.4

Established Pharmaceuticals sales increased 15.1 percent on a reported basis in the third quarter and increased 15.3 percent on an organic basis.

Key Emerging Markets include India, Brazil, Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 17.1 percent on a reported basis in the quarter and increased 17.9 percent on an organic basis. Organic sales growth was led by strong growth across several geographies, including China, Russia and India.

Other sales increased 9.7 percent on a reported basis in the quarter and increased 8.5 percent on an organic basis.



## Medical Devices

(\$ in millions)

	Sales 3Q21			% Change vs. 3Q20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total</b>	1,496	2,136	3,632	9.7	18.2	14.6	9.7	15.7	13.1
Rhythm Management	266	305	571	9.6	15.3	12.6	9.6	12.7	11.2
Electrophysiology	192	293	485	(0.1)	17.6	9.9	(0.1)	15.9	8.9
Heart Failure	170	59	229	17.6	28.0	20.1	17.6	25.4	19.5
Vascular	219	425	644	(4.3)	6.3	2.5	(4.3)	3.9	0.9
Structural Heart	177	215	392	11.2	10.9	11.0	11.2	9.2	10.1
Neuromodulation	149	41	190	(12.5)	13.8	(7.9)	(12.5)	11.5	(8.3)
Diabetes Care	323	798	1,121	43.1	29.4	33.0	43.1	26.0	30.6

	Sales 9M21			% Change vs. 9M20					
				Reported			Organic		
	U.S.	Int'l	Total	U.S.	Int'l	Total	U.S.	Int'l	Total
<b>Total</b>	4,385	6,233	10,618	23.1	25.5	24.5	23.1	19.0	20.7
Rhythm Management	776	881	1,657	18.5	21.2	19.9	18.5	14.9	16.6
Electrophysiology	580	823	1,403	21.8	26.2	24.4	21.8	20.9	21.3
Heart Failure	483	167	650	17.5	18.7	17.8	17.5	12.5	16.2
Vascular	684	1,292	1,976	8.9	16.7	13.9	8.9	11.2	10.4
Structural Heart	537	654	1,191	39.0	28.8	33.2	39.0	22.3	29.5
Neuromodulation	460	124	584	17.4	28.3	19.6	17.4	20.8	18.1
Diabetes Care	865	2,292	3,157	41.0	32.0	34.3	41.0	24.3	28.7

Worldwide Medical Devices sales increased 14.6 percent on a reported basis in the third quarter and increased 13.1 percent on an organic basis. Strong growth in the quarter was driven by continued recovery from the COVID-19 pandemic and strong growth in Diabetes Care.

Compared to pre-pandemic sales in 2019, Medical Devices sales increased 18.5 percent on a reported basis and 16.1 percent on an organic basis in the third quarter, led by double-digit growth in Electrophysiology, Heart Failure, Structural Heart and Diabetes Care.<sup>6</sup>

In Diabetes Care, FreeStyle Libre<sup>®</sup> and Libre Sense<sup>™</sup> sales were \$968 million in the quarter, which represents sales growth of 41.6 percent on a reported basis and 38.8 percent on an organic basis.

During the quarter, Abbott continued to strengthen its Medical Devices portfolio with several new products, including:

- U.S. FDA approval of Amplatzer Amulet Left Atrial Appendage Occluder to treat people with atrial fibrillation who are at risk of ischemic stroke.
- U.S. FDA approval of Portico with FlexNav transcatheter aortic valve replacement (TAVR) system to treat people with symptomatic, severe aortic stenosis who are at high risk for open-heart surgery.
- U.S. FDA approval of Amplatzer<sup>™</sup> Talisman<sup>™</sup> PFO Occlusion System to treat people with a patent foramen ovale – a small opening between the upper chambers of the heart – who are at risk of recurrent ischemic stroke.
- Abbott acquired Walk Vascular, LLC, a commercial-stage medical device company with a minimally invasive thrombectomy system designed to remove peripheral blood clots.

**ABBOTT'S EARNINGS-PER-SHARE GUIDANCE**

Abbott projects 2021 diluted earnings per share from continuing operations under GAAP of \$3.55 to \$3.65. Abbott forecasts specified items for the full-year 2021 of \$1.45 per share primarily related to intangible amortization, restructuring and cost reduction initiatives, including expenses to align its COVID-19 testing-related business with changes during the year in current and projected testing demand, expenses associated with acquisitions and other net expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be \$5.00 to \$5.10 for full-year 2021.

**ABBOTT DECLARES 391<sup>ST</sup> CONSECUTIVE QUARTERLY DIVIDEND**

On Sept. 15, 2021, the board of directors of Abbott declared the company's quarterly dividend of \$0.45 per share. Abbott's cash dividend is payable Nov. 15, 2021 to shareholders of record at the close of business on Oct. 15, 2021.

Abbott has increased its dividend payout for 49 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

**About Abbott:**

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at [www.abbott.com](http://www.abbott.com), on LinkedIn at [www.linkedin.com/company/abbott/](https://www.linkedin.com/company/abbott/), on Facebook at [www.facebook.com/Abbott](https://www.facebook.com/Abbott) and on Twitter @AbbottNews.

Abbott will live-webcast its third-quarter earnings conference call through its Investor Relations website at [www.abbottinvestor.com](http://www.abbottinvestor.com) at 8 a.m. Central time today. An archived edition of the webcast will be available later that day.

— Private Securities Litigation Reform Act of 1995 —  
A Caution Concerning Forward-Looking Statements

*Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2020, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.*

---

**Abbott Financial:**

Scott Leinenweber, 224-668-0791

Michael Comilla, 224-668-1872

Laura Dauer, 224-667-2299

**Abbott Media:**

Katie Stafford, 224-668-2121

Kate Dyer, 224-668-9965

- 
- 1 Third-quarter 2021 diluted EPS from continuing operations on a GAAP basis reflects 69.6 percent growth.
  - 2 Full-year 2021 guidance for diluted EPS from continuing operations on a GAAP basis reflects growth of 44.5 percent at the mid-point versus prior year.
  - 3 In the third quarter of 2019, worldwide sales were \$8.076 billion. In the third quarter of 2021, COVID-19 testing-related sales were \$1.908 billion. In the nine months of 2019, worldwide sales were \$23.590 billion. In the nine months of 2021, COVID-19 testing-related sales were \$5.360 billion.
  - 4 In the third quarter of 2020, Diagnostics sales were \$2.64 billion, which included COVID-19 testing-related sales of \$0.9 billion.
  - 5 In the third quarter of 2019, Core Laboratory and Molecular Diagnostics sales were \$1.177 billion and \$111 million, respectively. In the third quarter of 2021, COVID-19 testing-related sales for Core Laboratory and Molecular Diagnostics were \$47 million and \$218 million, respectively.
  - 6 In the third quarter of 2019, Medical Devices sales were \$3.065 billion.

Abbott Laboratories and Subsidiaries  
Condensed Consolidated Statement of Earnings  
Third Quarter Ended September 30, 2021 and 2020  
(in millions, except per share data)  
(unaudited)

	3Q21	3Q20	%
	\$	\$	Change
Net Sales	10,928	8,853	23.4
Cost of products sold, excluding amortization expense	4,423	3,966	11.5
Amortization of intangible assets	520	510	1.8
Research and development	672	580	16.1
Selling, general, and administrative	2,767	2,302	20.2
Total Operating Cost and Expenses	8,382	7,358	13.9
Operating Earnings	2,546	1,495	70.2
Interest expense, net	123	127	(3.3)
Net foreign exchange (gain) loss	4	(7)	n/m
Other (income) expense, net	(74)	(46)	63.1
Earnings from Continuing Operations before taxes	2,493	1,421	75.3
Tax expense on Earnings from Continuing Operations	393	189	107.3
Earnings from Continuing Operations	2,100	1,232	70.4
Earnings from Discontinued Operations, net of taxes	--	--	n/m
Net Earnings	2,100	1,232	70.4
Earnings from Continuing Operations, excluding Specified Items, as described below	2,518	1,760	43.1
Diluted Earnings per Common Share from:			
Continuing Operations	1.17	0.69	69.6
Discontinued Operations	--	--	n/m
Total	1.17	0.69	69.6
Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, as described below	1.40	0.98	42.9
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,789	1,788	

NOTES:

See tables on page 13 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

- 1) 2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately \$20 million in excess tax benefits associated with share-based compensation.
- 2) 2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of \$418 million, or \$0.23 per share, for intangible amortization and other expenses primarily associated with restructuring actions and acquisitions, partially offset by a change in estimate to the restructuring actions recognized in the second quarter related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.

2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of \$528 million, or \$0.29 per share, for intangible amortization and impairment expenses and other net expenses primarily associated with acquisitions, restructuring actions and income from a litigation settlement.

Abbott Laboratories and Subsidiaries  
Condensed Consolidated Statement of Earnings  
Nine Months Ended September 30, 2021 and 2020  
(in millions, except per share data)  
(unaudited)

	9M21	9M20	% Change
Net Sales	\$ 31,607	\$ 23,907	32.2
Cost of products sold, excluding amortization expense	13,771	10,510	31.0
Amortization of intangible assets	1,533	1,624	(5.7)
Research and development	1,980	1,722	15.0
Selling, general, and administrative	8,276	7,126	16.1
Total Operating Cost and Expenses	<u>25,560</u>	<u>20,982</u>	21.8
Operating Earnings	6,047	2,925	106.7
Interest expense, net	370	373	(0.7)
Net foreign exchange (gain) loss	7	(3)	n/m
Other (income) expense, net	(214)	(25)	n/m
Earnings from Continuing Operations before taxes	5,884	2,580	128.0
Tax expense on Earnings from Continuing Operations	802	267	n/m 1)
Earnings from Continuing Operations	5,082	2,313	119.7
Earnings from Discontinued Operations, net of taxes	--	20	n/m
Net Earnings	<u>\$ 5,082</u>	<u>\$ 2,333</u>	117.8
Earnings from Continuing Operations, excluding Specified Items, as described below	<u>\$ 7,001</u>	<u>\$ 3,940</u>	77.7 2)
Diluted Earnings per Common Share from:			
Continuing Operations	\$ 2.83	\$ 1.29	119.4
Discontinued Operations	--	0.01	n/m
Total	<u>\$ 2.83</u>	<u>\$ 1.30</u>	117.7
Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, as described below	<u>\$ 3.89</u>	<u>\$ 2.20</u>	76.8 2)
Average Number of Common Shares Outstanding			
Plus Dilutive Common Stock Options	1,791	1,785	

NOTES:

See tables on page 14 for an explanation of certain non-GAAP financial information.

n/m = Percent change is not meaningful.

See footnotes on the following page.

- 
- 1) 2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately \$97 million in excess tax benefits associated with share-based compensation.

2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately \$80 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately \$87 million in excess tax benefits associated with share-based compensation.

- 2) 2021 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of \$1.919 billion, or \$1.06 per share, for intangible amortization and other net expenses primarily associated with restructuring actions, certain litigation and acquisitions.

2020 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of \$1.627 billion, or \$0.91 per share, for intangible amortization expense, impairment charges and other net expense primarily associated with acquisitions, restructuring actions and income from a litigation settlement.

Abbott Laboratories and Subsidiaries  
Non-GAAP Reconciliation of Financial Information From Continuing Operations  
Third Quarter Ended September 30, 2021 and 2020  
(in millions, except per share data)  
(unaudited)

	3Q21			
	As Reported (GAAP)	Specified Items	As Adjusted	% to Sales
Intangible Amortization	\$ 520	\$ (520)	\$ --	
Gross Margin	5,985	445	6,430	58.8%
R&D	672	(21)	651	6.0%
SG&A	2,767	(30)	2,737	25.0%
Other (income) expense, net	(74)	7	(67)	
Earnings from Continuing Operations before taxes	2,493	489	2,982	
Tax expense on Earnings from Continuing Operations	393	71	464	
Earnings from Continuing Operations	2,100	418	2,518	
Diluted Earnings per Share from Continuing Operations	\$ 1.17	\$ 0.23	\$ 1.40	

Specified items reflect intangible amortization expense of \$520 million and net pretax income of \$31 million, primarily associated with a change in estimate to the restructuring actions recognized in the second quarter, partially offset by costs associated with acquisitions and other expenses. See page 16 for additional details regarding specified items.

	3Q20			
	As Reported (GAAP)	Specified Items	As Adjusted	% to Sales
Intangible Amortization	\$ 510	\$ (510)	\$ --	
Gross Margin	4,377	705	5,082	57.4%
R&D	580	(21)	559	6.3%
SG&A	2,302	63	2,365	26.7%
Other (income) expense, net	(46)	(1)	(47)	
Earnings from Continuing Operations before taxes	1,421	664	2,085	
Tax expense on Earnings from Continuing Operations	189	136	325	
Earnings from Continuing Operations	1,232	528	1,760	
Diluted Earnings per Share from Continuing Operations	\$ 0.69	\$ 0.29	\$ 0.98	

Specified items reflect intangible amortization expense of \$510 million and other net expenses of \$154 million, primarily associated with acquisitions, restructuring actions and other expenses and litigation settlement income. See page 17 for additional details regarding specified items.



Abbott Laboratories and Subsidiaries  
Non-GAAP Reconciliation of Financial Information From Continuing Operations  
Nine Months Ended September 30, 2021 and 2020  
(in millions, except per share data)  
(unaudited)

	9M21			
	As Reported (GAAP)	Specified Items	As Adjusted	% to Sales
Intangible Amortization	\$ 1,533	\$ (1,533)	\$ --	
Gross Margin	16,303	2,042	18,345	58.0%
R&D	1,980	(67)	1,913	6.1%
SG&A	8,276	(274)	8,002	25.3%
Other (income) expense, net	(214)	30	(184)	
Earnings from Continuing Operations before taxes	5,884	2,353	8,237	
Tax expense on Earnings from Continuing Operations	802	434	1,236	
Earnings from Continuing Operations	5,082	1,919	7,001	
Diluted Earnings per Share from Continuing Operations	\$ 2.83	\$ 1.06	\$ 3.89	

Specified items reflect intangible amortization expense of \$1.533 billion and other net expenses of \$820 million, primarily associated with restructuring actions, certain litigation, acquisitions and other expenses. See page 18 for additional details regarding specified items.

	9M20			
	As Reported (GAAP)	Specified Items	As Adjusted	% to Sales
Intangible Amortization	\$ 1,624	\$ (1,624)	\$ --	
Gross Margin	11,773	1,895	13,668	57.2%
R&D	1,722	(64)	1,658	6.9%
SG&A	7,126	(19)	7,107	29.7%
Other (income) expense, net	(25)	(111)	(136)	
Earnings from Continuing Operations before taxes	2,580	2,089	4,669	
Tax expense on Earnings from Continuing Operations	267	462	729	
Earnings from Continuing Operations	2,313	1,627	3,940	
Diluted Earnings per Share from Continuing Operations	\$ 1.29	\$ 0.91	\$ 2.20	

Specified items reflect intangible amortization expense of \$1.624 billion and other net expenses of \$465 million, primarily associated with acquisitions, restructuring actions and other expenses and litigation settlement income. See page 19 for additional details regarding specified items.

A reconciliation of the third-quarter tax rates for continuing operations for 2021 and 2020 is shown below:

(\$ in millions)	3Q21		
	Pre-Tax Income	Taxes on Earnings	Tax Rate
<b>As reported (GAAP)</b>	\$ 2,493	\$ 393	15.7%
Specified items	489	71	
<b>Excluding specified items</b>	\$ 2,982	\$ 464	15.5%

(\$ in millions)	3Q20		
	Pre-Tax Income	Taxes on Earnings	Tax Rate
<b>As reported (GAAP)</b>	\$ 1,421	\$ 189	13.3% 1)
Specified items	664	136	
<b>Excluding specified items</b>	\$ 2,085	\$ 325	15.6%

- 1) 2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately \$20 million in excess tax benefits associated with share-based compensation.

A reconciliation of the year-to-date tax rates for continuing operations for 2021 and 2020 is shown below:

(\$ in millions)	9M21		
	Pre-Tax Income	Taxes on Earnings	Tax Rate
<b>As reported (GAAP)</b>	\$ 5,884	\$ 802	13.6% 2)
Specified items	2,353	434	
<b>Excluding specified items</b>	\$ 8,237	\$ 1,236	15.0%

(\$ in millions)	9M20		
	Pre-Tax Income	Taxes on Earnings	Tax Rate
<b>As reported (GAAP)</b>	\$ 2,580	\$ 267	10.4% 3)
Specified items	2,089	462	
<b>Excluding specified items</b>	\$ 4,669	\$ 729	15.6%

- 2) 2021 Tax expense on Earnings from Continuing Operations includes the recognition of approximately \$97 million in excess tax benefits associated with share-based compensation.
- 3) 2020 Tax expense on Earnings from Continuing Operations includes the recognition of approximately \$80 million of net tax benefits as a result of the resolution of various tax positions related to prior years and approximately \$87 million in excess tax benefits associated with share-based compensation.

Abbott Laboratories and Subsidiaries  
Details of Specified Items  
Third Quarter Ended September 30, 2021  
(in millions, except per share data)  
(unaudited)

	Acquisition or Divestiture- related (a)	Restructuring and Cost Reduction Initiatives (b)	Intangible Amortization	Other (c)	Total Specifieds
Gross Margin	\$ 16	\$ (96)	\$ 520	\$ 5	\$ 445
R&D	(4)	--	--	(17)	(21)
SG&A	(12)	(23)	--	5	(30)
Other (income) expense, net	6	--	--	1	7
Earnings from Continuing Operations before taxes	<u>\$ 26</u>	<u>\$ (73)</u>	<u>\$ 520</u>	<u>\$ 16</u>	<u>489</u>
Tax expense on Earnings from Continuing Operations (d)					71
Earnings from Continuing Operations					<u>\$ 418</u>
Diluted Earnings per Share from Continuing Operations					<u>\$ 0.23</u>

The table above provides additional details regarding the specified items described on page 13.

- a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.
- b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes a credit associated with a change in estimate to the charges taken in the second quarter for a restructuring plan related to Abbott's manufacturing network for COVID-19 diagnostic tests to reflect current and projected demand.
- c) Other includes incremental costs to comply with the European Union's Medical Device (MDR) and In Vitro Diagnostics Medical Device (IVDR) Regulations for previously approved products.
- d) Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

Abbott Laboratories and Subsidiaries  
Details of Specified Items  
Third Quarter Ended September 30, 2020  
(in millions, except per share data)  
(unaudited)

	Acquisition or Divestiture- related (a)	Restructuring and Cost Reduction Initiatives (b)	Intangible Amortization	Other (c)	Total Specifieds
Gross Margin	\$ 16	\$ 27	\$ 510	\$ 152	\$ 705
R&D	(1)	(1)	--	(19)	(21)
SG&A	(28)	(9)	--	100	63
Other (income) expense, net	(2)	--	--	1	(1)
Earnings from Continuing Operations before taxes	<u>\$ 47</u>	<u>\$ 37</u>	<u>\$ 510</u>	<u>\$ 70</u>	<u>664</u>
Tax expense on Earnings from Continuing Operations (d)					136
Earnings from Continuing Operations					<u>\$ 528</u>
Diluted Earnings per Share from Continuing Operations					<u>\$ 0.29</u>

The table above provides additional details regarding the specified items described on page 13.

- a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention and the integration of systems, processes and business activities.
- b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.
- c) Other primarily relates to the impairment of an intangible asset and the costs to acquire R&D assets, partially offset by income from the settlement of litigation.
- d) Reflects the net tax benefit associated with the specified items, the resolution of prior years' tax positions and excess tax benefits associated with share-based compensation.

Abbott Laboratories and Subsidiaries  
Details of Specified Items  
Nine Months Ended September 30, 2021  
(in millions, except per share data)  
(unaudited)

	Acquisition or Divestiture- related (a)	Restructuring and Cost Reduction Initiatives (b)	Intangible Amortization	Other (c)	Total Specifieds
Gross Margin	\$ 56	\$ 433	\$ 1,533	\$ 20	\$ 2,042
R&D	(9)	1	--	(59)	(67)
SG&A	(43)	(22)	--	(209)	(274)
Other (income) expense, net	3	1	--	26	30
Earnings from Continuing Operations before taxes	<u>\$ 105</u>	<u>\$ 453</u>	<u>\$ 1,533</u>	<u>\$ 262</u>	<u>2,353</u>
Tax expense on Earnings from Continuing Operations (d)					434
Earnings from Continuing Operations					<u>\$ 1,919</u>
Diluted Earnings per Share from Continuing Operations					<u>\$ 1.06</u>

The table above provides additional details regarding the specified items described on page 14.

- a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities.
- b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. The Gross Margin amount includes charges associated with a restructuring plan to align Abbott's manufacturing network for COVID-19 diagnostic tests with changes during the year in current and projected testing demand.
- c) Other primarily relates to the costs related to certain litigation, the acquisition of a research and development asset, the impairments of an equity investment and an intangible asset, and the gain on the disposition of an equity method investment.
- d) Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation.

Abbott Laboratories and Subsidiaries  
Details of Specified Items  
Nine Months Ended September 30, 2020  
(in millions, except per share data)  
(unaudited)

	Acquisition or Divestiture- related (a)	Restructuring and Cost Reduction Initiatives (b)	Intangible Amortization	Other (c)	Total Specifieds
Gross Margin	\$ 61	\$ 57	\$ 1,624	\$ 153	\$ 1,895
R&D	(8)	(9)	--	(47)	(64)
SG&A	(83)	(36)	--	100	(19)
Other (income) expense, net	(3)	--	--	(108)	(111)
Earnings from Continuing Operations before taxes	<u>\$ 155</u>	<u>\$ 102</u>	<u>\$ 1,624</u>	<u>\$ 208</u>	<u>2,089</u>
Tax expense on Earnings from Continuing Operations (d)					462
Earnings from Continuing Operations					<u>\$ 1,627</u>
Diluted Earnings per Share from Continuing Operations					<u>\$ 0.91</u>

The table above provides additional details regarding the specified items described on page 14.

- a) Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities.
- b) Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites.
- c) Other primarily relates to impairment charges related to certain assets and the costs to acquire R&D assets, partially offset by income from the settlement of litigation.
- d) Reflects the net tax benefit associated with the specified items, the resolution of prior years' tax positions and excess tax benefits associated with share-based compensation.

###